APOBEC3G and acute myeloid leukemia: The results indicated that the expression level of APOBEC3B has no direct relation to poor overall survival (OS) for patients with AML (HR (high) = 1.01; p = 0.981, Figure 2E); however, high APOBEC3G expression was considerably associated with the short OS of AML patients (Hazard ratio; HR) (high) = 1.89; p = 0.004, Figure 2F) compared with the low expression group.